Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)
Issues related to biosecurity;
H.R. 7085/S. 3558, BIOSECURE Act
Duration: January 18, 2019
to
present
General Issues: Health Issues , Homeland Security , Defense , Labor Issues/Antitrust/Workplace , Veterans , Medicare/Medicaid , Budget/Appropriations , Medical/Disease Research/Clinical Labs
Spending: about $1,260,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: House of Representatives, U.S. Senate, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Tracy Spicer Dep. Chief of Staff, Political Director, Legislative Assistant, Special Assistant, Staff Assistant - Sen. Edward M. Kennedy
Elizabeth Barnett Speechwriter, Legislative Correspondent, Legislative Assistant - Sen. Blanche Lincoln; Staff Assistant - Sen. Committee on Energy and Natural Resources
Amy Tejral Legislative Director, Sen. Ben Nelson
Jordan LaCrosse n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on April 22.
Original Filing: 301574313.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to biosecurity;
H.R. 7085/S. 3558, BIOSECURE Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Jan. 22.
Original Filing: 301539424.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues to related to Biotechnology and Biosecurity best practices;
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Biotech issues related to the National Defense Authorization Act
3rd Quarter, 2023
In Q3, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301515849.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues to related to Biotechnology and Biosecurity best practices;
Issues related to the White House Cancer Moonshot initiative;
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the National Defense Authorization Act
2nd Quarter, 2023
In Q2, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on July 20, 2023.
Original Filing: 301491242.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues to related to Biotechnology and Biosecurity best practices;
Issues related to the White House Cancer Moonshot initiative;
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301464286.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues to related to Biotechnology and Biosecurity best practices;
Issues related to the White House Cancer Moonshot initiative;
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439682.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Issues to related to Biotechnology and Biosecurity best practices;
S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
H.R. 7007, COVID Supplemental Appropriations Act, 2022;
S. 3799, PREVENT Pandemics Act;
H.R. 791/S. 236, Tracking COVID-19 Variants Act;
S.3534/H.R.7152, Tracking Pathogens Act;
Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act
H. Rpt. 107-443, Explanatory Statement accompanying Division H - Departments of Labor, Health and Human Services, and Education, and related Agencies Appropriations Act, 2023 - related to whole genome sequencing
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413680.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
S. 2022, Ending the Diagnostic Odyssey Act;
H.R. 6000, Cures 2.0 Act;
Ongoing monitoring of CDC surveillance funding;
Chips and Science Act (PL 117-167);
H.R. 791/S. 236, Tracking COVID-19 Variants Act;
H.R. 5376, Inflation Reduction Act of 2022;
H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act;
S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
H.R. 7007, COVID Supplemental Appropriations Act, 2022;
S. 3799, PREVENT Pandemics Act;
Issues related to the FY 2023 President's Budget;
S.3534/H.R.7152, Tracking Pathogens Act;
Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301392688.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
S. 2022, Ending the Diagnostic Odyssey Act;
H.R. 6000, Cures 2.0 Act;
Ongoing monitoring of CDC surveillance funding;
Monitor Conference negotiations between H.R. 4521, America COMPETES Act of 2022 and S. 1260, United States Innovation and Competition Act of 2021 and their efforts to bolster US competitiveness against China in critical technology sectors;
H.R.791/S.236, Tracking COVID-19 Variants Act;
H.R. 5376, Build Back Better Act;
H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act;
S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
H.R. 7007, COVID Supplemental Appropriations Act, 2022;
S. 3799, PREVENT Pandemics Act;
Issues related to the FY 2023 Presidents Budget
S.3534/H.R.7152, Tracking Pathogens Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301371009.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
S. 2022, Ending the Diagnostic Odyssey Act;
H.R. 6000, Cures 2.0 Act;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Ongoing monitoring of CDC surveillance funding;
Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors;
Monitor H.R. 2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;
Monitor H.R. 4521, America COMPETES Act of 2022 and efforts to bolster US competitiveness against China in critical technology sectors;
H.R.791/S.236, Tracking COVID-19 Variants Act;
H.R. 5376, Build Back Better Act;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
H.R. 7007, COVID Supplemental Appropriations Act, 2022;
S. 3799, PREVENT Pandemics Act;
Issues related to the FY 2023 Presidents Budget
S.3534/H.R.7152, Tracking Pathogens Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329979.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
S. 2022, Ending the Diagnostic Odyssey Act;
CURES 2.0 Discussion Draft;
Implementation of PL 117-2, American Rescue Plan Act of 2021;
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Ongoing monitoring of CDC surveillance funding;
Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors;
Monitor H.R. 2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;
H.R.791/S.236, Tracking COVID-19 Variants Act;
H.R. 5376, Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313619.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
S. 2022, Ending the Diagnostic Odyssey Act;
CURES 2.0 Discussion Draft;
Implementation of PL 117-2, American Rescue Plan Act of 2021;
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Ongoing monitoring of CDC surveillance funding;
Monitor S. 1260, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;
H.R.791/S.236, Tracking COVID-19 Variants Act;
H.R. 5376, Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301289749.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
S. 2022, Ending the Diagnostic Odyssey Act;
CURES 2.0 Discussion Draft;
Implementation of PL 117-2, American Rescue Plan Act of 2021;
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Ongoing monitoring of CDC surveillance funding;
Monitor S. 1260, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors;
H.R.791/S.236, Tracking COVID-19 Variants Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to FTC, mergers, antitrust
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2021
In Q1, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301262103.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
Reintroduction of Ending the Diagnostic Odyssey Act;
H.R.1319, American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Ongoing monitoring of CDC surveillance funding;
Monitor Endless Frontier Act (Schumer/Young) and efforts to bolster US competitiveness against China in critical technology sectors;
H.R.791/S.236, Tracking COVID-19 Variants Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Jan. 21, 2021.
Original Filing: 301244140.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;
Public Law 116-136 - CARES Act;
Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act;
H.R. 6800, The Heroes Act;
H.R. 925, The Heroes Act;
CDC surveillance funding;
CURES 2.0 discussion draft;
H.R. 133/P.L. 116-260, Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Million Veterans Program (MVP) - issues related to precision medicine
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222939.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement;
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;
Public Law 116-136 - CARES Act;
Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act;
H.R. 6800, The Heroes Act;
H.R. 925, The Heroes Act;
CDC surveillance funding;
CURES 2.0 discussion draft
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301201559.xml
Lobbying Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement. H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;
Public Law 116-136 - CARES Act;
Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act;
H.R.6800, The Heroes Act;
CDC surveillance funding
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301173758.xml
Lobbying Issues
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019;
H.R. 748 (Public Law 116-136), CARES Act - issues related to Next Generation Sequencing (NGS) and surveillance funding
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Jan. 18, 2020.
Original Filing: 301120914.xml
Lobbying Issues
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068901.xml
Lobbying Issues
Policies impacting Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services;
H.R. 4144, Ending the Diagnostic Odyssey Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Institutes of Health (NIH) funding/All of Me program
2nd Quarter, 2019
In Q2, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on July 19, 2019.
Original Filing: 301052664.xml
Lobbying Issues
Issues related to genetic sequencing industry and the use of genetic information in research and clinical settings;
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Institutes of Health (NIH) funding
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, Avenue Solutions lobbied for Illumina, Inc. , earning $60,000. The report was filed on April 19, 2019.
Original Filing: 301031130.xml
Lobbying Issues
Issues related to genetic sequencing industry and the use of genetic information in research and clinical settings;
Discussions around reintroduction of H.R. 5062, Advancing Access to Precision Medicine Act from 115th Congress
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs/Medicaid
1st Quarter, 2019
Avenue Solutions filed a lobbying registration on Feb. 21, 2019 to represent Illumina, Inc., effective Jan. 18, 2019.
Original Filing: 301020595.xml
Issue(s) they said they’d lobby about: Issues related to the genetic sequencing industry and the use of genetic information in research and clinical settings. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...